Natera (NASDAQ:NTRA) Insider Sells 1,010 Shares of Company Stock

Key Points

• Natera insider Solomon Moshkevich sold 1,010 shares at an average price of $406, generating $410,060. The transaction was made under a pre-arranged Rule 10b5-1 plan to cover tax withholding, reducing his holdings by 0.94% to 105,904 shares.
• Natera shares rose to $436, near their 52-week high of $437.41, while the company’s latest quarterly revenue increased 37.7% year over year to $752.75 million and exceeded analyst estimates.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $394.31, although ratings range from “Strong Buy” to “Strong Sell” and the company continues to report negative earnings.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider Solomon Moshkevich sold 1,010 shares of the firm's stock in a transaction on Tuesday, October 27th. The stock was sold at an average price of $406.00, for a total value of $410,060.00. Following the completion of the sale, the insider directly owned 105,904 shares of the company's stock, valued at approximately $42,997,024. This trade represents a 0.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Solomon Moshkevich also recently made the following trade(s):

• On Wednesday, October 28th, Solomon Moshkevich sold 1,162 shares of Natera stock. The shares were sold at an average price of $426.34, for a total value of $495,407.08.
• On Thursday, October 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $414.22, for a total value of $1,242,660.00.
• On Wednesday, September 2nd, Solomon Moshkevich sold 15,160 shares of Natera stock. The stock was sold at an average price of $326.89, for a total value of $4,955,652.40.
• On Tuesday, September 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $320.73, for a total value of $962,190.00.
• On Monday, August 3rd, Solomon Moshkevich sold 3,410 shares of Natera stock. The shares were sold at an average price of $265.58, for a total value of $905,627.80.

Natera Price Performance

Shares of NTRA traded up $11.58 during trading hours on Thursday, reaching $436.00. The company's stock had a trading volume of 1,325,469 shares, compared to its average volume of 1,585,948. Natera, Inc. has a 1-year low of $181.00 and a 1-year high of $437.41. The company has a 50 day moving average of $375.27 and a two-hundred day moving average of $265.54.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.49) by $0.02. The business had revenue of $752.75 million during the quarter, compared to analyst estimates of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The firm's revenue was up 37.7% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.74) earnings per share. Equities research analysts expect that Natera, Inc. will post -1.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of NTRA. SYM FINANCIAL Corp lifted its stake in shares of Natera by 1.7% in the 3rd quarter. SYM FINANCIAL Corp now owns 1,897 shares of the medical research company's stock valued at $784,000 after purchasing an additional 32 shares during the last quarter. Versant Capital Management Inc increased its position in Natera by 4.6% during the third quarter. Versant Capital Management Inc now owns 815 shares of the medical research company's stock worth $337,000 after buying an additional 36 shares during the last quarter. VestGen Advisors LLC increased its position in Natera by 3.1% during the third quarter. VestGen Advisors LLC now owns 1,460 shares of the medical research company's stock worth $603,000 after buying an additional 44 shares during the last quarter. Parallel Advisors LLC raised its holdings in Natera by 5.5% during the first quarter. Parallel Advisors LLC now owns 905 shares of the medical research company's stock valued at $181,000 after buying an additional 47 shares in the last quarter. Finally, Raiffeisen Bank International AG raised its holdings in Natera by 48.5% during the second quarter. Raiffeisen Bank International AG now owns 150 shares of the medical research company's stock valued at $41,000 after buying an additional 49 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on NTRA. BTIG Research lifted their target price on shares of Natera from $320.00 to $430.00 and gave the company a "buy" rating in a research note on Tuesday. Guggenheim increased their price objective on Natera from $360.00 to $475.00 and gave the stock a "buy" rating in a report on Thursday, October 1st. Wells Fargo & Company lifted their price objective on Natera from $220.00 to $284.00 and gave the company an "equal weight" rating in a research report on Friday, August 7th. Evercore restated an "outperform" rating and issued a $300.00 target price on shares of Natera in a research note on Monday, July 6th. Finally, Zacks Research lowered Natera from a "hold" rating to a "strong sell" rating in a research report on Friday, October 16th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $394.31.

Key Stories Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera presented 25 abstracts at the ESMO oncology conference, highlighting additional Signatera data and supporting the test’s potential commercial and clinical adoption. Natera presents 25 ESMO abstracts
• Positive Sentiment: Investors reacted favorably to Signatera clinical and regulatory wins, which could strengthen Natera’s competitive position in minimal residual disease testing and support future revenue growth. Investors React to Signatera Wins
• Positive Sentiment: The third-quarter outlook centers on continued Signatera volume growth, higher test prices, regulatory progress and expanding Medicare coverage that could benefit Natera’s organ-health business. NTRA Q3 Earnings Preview
• Neutral Sentiment: Natera will release third-quarter 2026 results on November 5 after the market closes, giving investors a near-term catalyst to assess testing volumes, reimbursement trends and profitability. Natera Q3 Results Announcement
• Negative Sentiment: Zacks cautions that Natera may report negative earnings and lacks the typical combination of estimate revisions and momentum associated with a likely earnings beat, raising the risk of volatility around the report. Natera Earnings Beat Outlook
• Negative Sentiment: One valuation analysis estimates NTRA could be about 32% below fair value based on ESMO-related data, suggesting the stock’s gains may have outpaced its fundamentals. Natera Fair Value Analysis
• Negative Sentiment: Two company officers disclosed plans to sell a combined 1,768 shares, including 771 shares valued at approximately $312,000; the transactions are relatively small but may modestly weigh on sentiment. John Fesko Share Sale Solomon Moshkevich Share Sale

Natera Company Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.